Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subgroups: Insights From a Single-Center Cohort
Authors' conclusion
Remission rates differed across IIM subgroups, with the highest in DM and lowest in ASyS. Anti-Mi-2 antibody was associated with a higher likelihood of remission.
Study context
- Population
- Adults with idiopathic inflammatory myopathy (IIM) with ≥ 1 year of disease duration, enrolled 2000–2019 in a prospective registry67.2% female
- Participants
- 393 adults
- Exposure
- Remission rates and predictors across IIM subgroups
- Outcome
- Remission (absence of disease activity by expert assessment)
- Follow-up
- 10 years
Methodological detailssingle-centre, prospective registry, cumulative incidence function, cause-specific Cox proportional hazards models, remission as time-dependent covariate
- Single-centre
- Prospective registry
- Cumulative incidence function
- Cause-specific Cox proportional hazards models
- Remission as time-dependent covariate
Main finding
As reported in the abstract
Cumulative probability of remission
- Remission, whole cohort
- 40.3%
- Drug-free remission (DFR), whole cohort
- 23.3%
- IMACS remission (≥ 6 months of DFR), whole cohort
- 18.1%
Observational data: associations, not effects.
Further findings
| Outcome | HR for remission | P value |
|---|---|---|
| Predictor of remission: anti-Mi-2 antibodyCause-specific Cox model; higher likelihood of remission | 2.08 | P = 0.02 |
10-year cumulative probability of DFR and IMACS remission (≥ 6 months of DFR)
- DFR
- 23.3%
- IMACS remission
- 18.1%
Remission rates by IIM subgroup
- Highest in dermatomyositis (DM), lowest in antisynthetase syndrome (ASyS)
Median time to first remission
- Median time to first remission
- 3.7 years
10-year cumulative incidence of flare following remission
- Flare after remission
- 40.6%
Remission, DFR and mortality
- Remission and DFR associated with improved survival
Original publication
Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subgroups: Insights From a Single-Center Cohort. J Rheumatol. Published 15 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →